nevena damianov, md on the reasoning for studying pd-l1 inhibition in advanced hcc
Published 8 years ago • 7 plays • Length 0:49
Download video MP4
Download video MP3
Similar videos
-
1:00
nevena damianov, md illustrates the promising classes and products for advanced, unresectable hcc
-
1:13
nevena damianov, md interprets how new advanced hcc agents will integrate into hcc treatment
-
1:47
nevena damjanov, md, discusses how new agents for advanced hcc will be integrated into the treatment
-
0:42
nevena damianov, md relays which late stage clinical studies will impact in advanced hcc
-
0:44
nevena damianov, md discusses the toxicity concerns and how to manage them for sorafenib in hcc
-
0:35
nevena damjanov, md, on the use of pembrolizumab in hcc patients previously treated with sorafenib
-
1:14
nevena damjanov, md, on the phase 3 checkpoint 459 trial studying nivolumab in hcc
-
1:16
nevena damjanov, md, discusses current treatment options and sequencing tkis in hcc
-
0:47
nevena damjanov, md, discusses identifying subgroups of patients for targeted therapies in hcc
-
0:49
nevena damjanov, md, considers the shortcomings of recist in measuring efficacy in hcc patients
-
0:35
nevena damjanov, md, elaborates on stereotactic body radiation therapy in early stage hcc
-
1:57
dr. pinato on pd-l1 testing in hcc
-
1:13
nevena damjanov, md, comments on identifying subgroups of patients for targeted therapies in hcc
-
0:46
nevena damjanov, md, outlines the role of tace with systemic therapy in hcc patients
-
0:54
nevena damjanov, md, regarding sequencing tkis in hepatocellular carcinoma (hcc)
-
44:44
the increasing role of immunotherapy in the management of hcc
-
2:26
dr. abou-alfa discusses ongoing studies of immunotherapy in hcc
-
1:29
nevena damjanov, md, shares her impressions of lenvatinib data in 1st line uhcc presented at asco
-
40:41
roxana dronca md discusses sequencing vegf and pd-1 inhibition
Clip.africa.com - Privacy-policy